Intercept Pharmaceuticals Inc
F:I4P
Intercept Pharmaceuticals Inc
Research & Development
Intercept Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Intercept Pharmaceuticals Inc
F:I4P
|
Research & Development
-$160.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-21%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$8.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Intercept Pharmaceuticals Inc
Glance View
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 437 full-time employees. The company went IPO on 2012-10-11. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The firm is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. The Company’s other compounds are in early stages of research and development pipeline, including INT-787 compound, an FXR agonist is in a Phase I clinical trial.
See Also
What is Intercept Pharmaceuticals Inc's Research & Development?
Research & Development
-160.4m
USD
Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Research & Development amounts to -160.4m USD.
What is Intercept Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-21%
Over the last year, the Research & Development growth was 14%. The average annual Research & Development growth rates for Intercept Pharmaceuticals Inc have been 8% over the past three years , 4% over the past five years , and -21% over the past ten years .
